Non Hodgkin Lymphoma Clinical Trial
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Summary
The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.
Eligibility Criteria
Inclusion Criteria:
Diagnosed with diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma or transformed follicular lymphoma
Scheduled to receive commercial axi-cel at Moffitt Cancer Center
Able to speak and read standard english
Have no documented or observable psychiatric or neurological diagnoses that interfere with study participation (e.g., schizophrenia)
Have no history of traumatic brain injury, stroke, or dementia
Able to provide informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Tampa Florida, 33612, United States
How clear is this clinincal trial information?